CARTITUDE-1 evaluated cilta-cel in 97 heavily pretreated patients with RRMM. Of these patients, 32 (33%) remained progression-free for ≥5 years after cilta-cel, without further MM treatment. While patients with HRCA/EMD were equally likely to be progression-free, patients with a higher post-infusion effector:target ratio of either CAR+ T cells or CAR+ CD4+ T cells with central memory phenotype at peak expansion were significantly associated with long-term disease control.

Abbreviations
CAR, chimeric antigen receptor; cilta-cel, ciltacabtagene autoleucel; EMD, extramedullary disease; HRCA, high risk cytogenetic abnormalities; MM, multiple myeloma; RRMM, relapsed/refractory MM.

Reference
Voorhees P, et al. Presented at: ASCO, Chicago, IL, USA. 30 May–3 June 2025. Abstr. 7507.

A retrospective study investigated the efficacy and toxicity of BCMA-targeting BsAbs following GPRC5D-targeting BsAbs in patients with RRMM (N=26).¹ An ORR of 58% was observed, which is similar to the rates reported in the original pivotal trials (elranatamab, 61%;² teclistamab, 63% ³).¹ No new toxicities beyond those previously reported were observed.1 The data from this real-world study support the sequencing of BsAbs as a viable strategy in the treatment of RRMM.¹

Abbreviations
BCMA, B-cell maturation antigen; BsAb, bispecific antibody; GPRC5D, G protein-coupled receptor, class C, group 5, member D; ORR, objective response rate; RRMM, relapsed/refractory multiple myeloma.

References

1. Hulin C, et al. Presented at: EHA, Milan, Italy. 12–15 June 2025. Abstr. PS1721.
2. Lesokhin AM, et al. Nat Med. 2023;29:2259–67.
3. Moreau P, et al. N Engl J Med. 2022;387:495–505.

REALiTEC is a retrospective, international, non-interventional study describing the management and outcomes of patients treated with teclistamab outside of clinical trials (N=113). Infections were the most common AEs (any grade, 71%; grade ≥3, 39%), with the incidence of grade ≥3 infections highest in the first 6 months. Overall infection rates declined over time. IVIg was used in up to 60% of patients, highlighting the importance of supportive care in maintaining patients on treatment to achieve deep and durable responses.

Abbreviations
AE, adverse event; IVIg, intravenous immunoglobulin.

Reference
Perrot A, et al. Presented at: COMy, Paris, France. 15–18 May 2025. Abstr. 55.

The phase III DREAMM-8 trial investigated the efficacy and safety of BPd (n=155) versus PVd (n=147) in patients with RRMM who received ≥1 LoT, including lenalidomide. At a median follow-up of 28 months, mPFS was 32.6 months (95% CI, 21.1–NR) for BPd versus 12.5 months (95% CI, 9.1–17.6) for PVd. PFS benefit extended to all subgroups, including patients with high-risk cytogenetics, lenalidomide-refractory disease and ≥2 prior LoT.

Abbreviations
BPd, belantamab mafodotin, pomalidomide and dexamethasone; CI, confidence interval; LoT, lines of therapy; m, median; NR, not reached; PFS, progression-free survival; PVd, pomalidomide, bortezomib and dexamethasone; RRMM, relapsed/refractory multiple myeloma.

Reference
Dimopoulos E, et al. Presented at: EHA, Milan, Italy. 12–15 June 2025. Abstr. PF728.

JNJ-5322 is a next-generation TsAb designed to enhance on-tumour effects and reduce off-tumour impact through comprehensive dual targeting of BCMA and GPRC5D via T-cell redirection, incorporating novel binding domains, including low-affinity CD3.

Abbreviations
BCMA, B-cell maturation antigen; GPRC5D, G protein-coupled receptor, class C, group 5, member D; TsAb, trispecific antibody.

Reference
van de Donk NWCJ, et al. Presented at: 2025 ASCO, Chicago, IL, USA. 30 May–3 June 2025. Abstr. 7505.